Literature DB >> 18606301

Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.

Matteo M Guerrini1, Cristina Sobacchi, Barbara Cassani, Mario Abinun, Sara S Kilic, Alessandra Pangrazio, Daniele Moratto, Evelina Mazzolari, Jill Clayton-Smith, Paul Orchard, Fraser P Coxon, Miep H Helfrich, Julie C Crockett, David Mellis, Ashok Vellodi, Ilhan Tezcan, Luigi D Notarangelo, Michael J Rogers, Paolo Vezzoni, Anna Villa, Annalisa Frattini.   

Abstract

Autosomal-Recessive Osteopetrosis (ARO) comprises a heterogeneous group of bone diseases for which mutations in five genes are known as causative. Most ARO are classified as osteoclast-rich, but recently a subset of osteoclast-poor ARO has been recognized as due to a defect in TNFSF11 (also called RANKL or TRANCE, coding for the RANKL protein), a master gene driving osteoclast differentiation along the RANKL-RANK axis. RANKL and RANK (coded for by the TNFRSF11A gene) also play a role in the immune system, which raises the possibility that defects in this pathway might cause osteopetrosis with immunodeficiency. From a large series of ARO patients we selected a Turkish consanguineous family with two siblings affected by ARO and hypogammaglobulinemia with no defects in known osteopetrosis genes. Sequencing of genes involved in the RANKL downstream pathway identified a homozygous mutation in the TNFRSF11A gene in both siblings. Their monocytes failed to differentiate in vitro into osteoclasts upon exposure to M-CSF and RANKL, in keeping with an osteoclast-intrinsic defect. Immunological analysis showed that their hypogammaglobulinemia was associated with impairment in immunoglobulin-secreting B cells. Investigation of other patients revealed a defect in both TNFRSF11A alleles in six additional, unrelated families. Our results indicate that TNFRSF11A mutations can cause a clinical condition in which severe ARO is associated with an immunoglobulin-production defect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18606301      PMCID: PMC2443850          DOI: 10.1016/j.ajhg.2008.06.015

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  23 in total

1.  In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.

Authors:  Harry C Blair; Christopher W Borysenko; Anna Villa; Paul H Schlesinger; Sara E Kalla; Beatrice B Yaroslavskiy; Verónica Garćia-Palacios; Jennifer I Oakley; Paul J Orchard
Journal:  J Bone Miner Res       Date:  2004-04-05       Impact factor: 6.741

2.  A novel method for efficient generation of transfected human osteoclasts.

Authors:  A Taylor; M J Rogers; D Tosh; F P Coxon
Journal:  Calcif Tissue Int       Date:  2007-02-03       Impact factor: 4.333

3.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.

Authors:  A E Hughes; S H Ralston; J Marken; C Bell; H MacPherson; R G Wallace; W van Hul; M P Whyte; K Nakatsuka; L Hovy; D M Anderson
Journal:  Nat Genet       Date:  2000-01       Impact factor: 38.330

4.  Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man.

Authors:  U Kornak; D Kasper; M R Bösl; E Kaiser; M Schweizer; A Schulz; W Friedrich; G Delling; T J Jentsch
Journal:  Cell       Date:  2001-01-26       Impact factor: 41.582

5.  Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene.

Authors:  N Kim; P R Odgren; D K Kim; S C Marks; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  Functional identification of three receptor activator of NF-kappa B cytoplasmic motifs mediating osteoclast differentiation and function.

Authors:  Wei Liu; Duorong Xu; Hongmei Yang; Hui Xu; Zhenqi Shi; Xuemei Cao; Sunao Takeshita; Jianzhong Liu; Michael Teale; Xu Feng
Journal:  J Biol Chem       Date:  2004-10-12       Impact factor: 5.157

7.  Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene.

Authors:  Kiyoshi Nakatsuka; Yoshiki Nishizawa; Stuart H Ralston
Journal:  J Bone Miner Res       Date:  2003-08       Impact factor: 6.741

8.  Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans.

Authors:  Liesbeth Van Wesenbeeck; Paul R Odgren; Fraser P Coxon; Annalisa Frattini; Pierre Moens; Bram Perdu; Carole A MacKay; Els Van Hul; Jean-Pierre Timmermans; Filip Vanhoenacker; Ruben Jacobs; Barbara Peruzzi; Anna Teti; Miep H Helfrich; Michael J Rogers; Anna Villa; Wim Van Hul
Journal:  J Clin Invest       Date:  2007-04       Impact factor: 14.808

9.  Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE.

Authors:  D Kim; R E Mebius; J D MacMicking; S Jung; T Cupedo; Y Castellanos; J Rho; B R Wong; R Josien; N Kim; P D Rennert; Y Choi
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

10.  RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla.

Authors:  Simona W Rossi; Mi-Yeon Kim; Andreas Leibbrandt; Sonia M Parnell; William E Jenkinson; Stephanie H Glanville; Fiona M McConnell; Hamish S Scott; Josef M Penninger; Eric J Jenkinson; Peter J L Lane; Graham Anderson
Journal:  J Exp Med       Date:  2007-05-14       Impact factor: 14.307

View more
  83 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

Review 2.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

3.  The IVVY Motif and Tumor Necrosis Factor Receptor-associated Factor (TRAF) Sites in the Cytoplasmic Domain of the Receptor Activator of Nuclear Factor κB (RANK) Cooperate to Induce Osteoclastogenesis.

Authors:  Joel Jules; Shunqing Wang; Zhenqi Shi; Jianzhong Liu; Shi Wei; Xu Feng
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

4.  Receptor activator of NF-{kappa}B (RANK) cytoplasmic IVVY535-538 motif plays an essential role in tumor necrosis factor-{alpha} (TNF)-mediated osteoclastogenesis.

Authors:  Joel Jules; Zhenqi Shi; Jianzhong Liu; Duorong Xu; Shunqing Wang; Xu Feng
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

5.  Osteoclasts and hematopoiesis.

Authors:  Anna Teti
Journal:  Bonekey Rep       Date:  2012-03-28

6.  Novel mutation of TCIRG1 and clinical pictures of two infantile malignant osteopetrosis patients.

Authors:  Ping Yuan; Zhihui Yue; Liangzhong Sun; Weijun Huang; Bin Hu; Zhiyun Yang; Yuelin Hu; Hua Xiao; Hui Shi; Qing Zhou; Yiming Wang
Journal:  J Bone Miner Metab       Date:  2010-11-02       Impact factor: 2.626

7.  RANK/RANKL Acts as a Protective Factor by Targeting Cholangiocytes in Primary Biliary Cholangitis.

Authors:  Yan-Li Hao; Zhao-Lian Bian; Lin-Ling Ju; Yuan Liu; Gang Qin
Journal:  Dig Dis Sci       Date:  2019-08-03       Impact factor: 3.199

Review 8.  Nuclear receptors in bone physiology and diseases.

Authors:  Yuuki Imai; Min-Young Youn; Kazuki Inoue; Ichiro Takada; Alexander Kouzmenko; Shigeaki Kato
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

Review 9.  Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

Authors:  T Segovia-Silvestre; A V Neutzsky-Wulff; M G Sorensen; C Christiansen; J Bollerslev; M A Karsdal; K Henriksen
Journal:  Hum Genet       Date:  2008-11-06       Impact factor: 4.132

10.  A genome-wide association study of myasthenia gravis.

Authors:  Alan E Renton; Hannah A Pliner; Carlo Provenzano; Amelia Evoli; Roberta Ricciardi; Michael A Nalls; Giuseppe Marangi; Yevgeniya Abramzon; Sampath Arepalli; Sean Chong; Dena G Hernandez; Janel O Johnson; Emanuela Bartoccioni; Flavia Scuderi; Michelangelo Maestri; J Raphael Gibbs; Edoardo Errichiello; Adriano Chiò; Gabriella Restagno; Mario Sabatelli; Mark Macek; Sonja W Scholz; Andrea Corse; Vinay Chaudhry; Michael Benatar; Richard J Barohn; April McVey; Mamatha Pasnoor; Mazen M Dimachkie; Julie Rowin; John Kissel; Miriam Freimer; Henry J Kaminski; Donald B Sanders; Bernadette Lipscomb; Janice M Massey; Manisha Chopra; James F Howard; Wilma J Koopman; Michael W Nicolle; Robert M Pascuzzi; Alan Pestronk; Charlie Wulf; Julaine Florence; Derrick Blackmore; Aimee Soloway; Zaeem Siddiqi; Srikanth Muppidi; Gil Wolfe; David Richman; Michelle M Mezei; Theresa Jiwa; Joel Oger; Daniel B Drachman; Bryan J Traynor
Journal:  JAMA Neurol       Date:  2015-04       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.